Search Results
Jun 05, 2026, 20:30 ET Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
validated platform technology developed by Dr. Long-Cheng Li and his team. It utilizes small activating RNAs (saRNAs) to target gene regulatory domains, robustly activating endogenous gene expression and restoring therapeutic protein levels. This innovative technology holds vast potential for developing disease-modifying
More news about: Ractigen Therapeutics
Jun 05, 2026, 12:21 ET O CERAVE CELEBRA MAIS DE 100 CRIADORES DE CONTEÚDO PREMIADOS DE 22 PAÍSES PELOS PRIMEIROS CERAWARDS GLOBAIS
cerimônia contou com um painel de jurados global, incluindo a atriz Bailee Madison, dermatologista e criador certificado pelo conselho, Dr. Andrew Park, e Gene Colón - vice-presidente sênior global de assuntos médicos e comunicações da CeraVe.A cerimônia coroou os vencedores inaugurais do Global CerAwards,
More news about: CeraVe
Jun 05, 2026, 12:04 ET CeraVe premia a más de 100 creadores de contenido galardonados de 22 países en los CerAwards
Stalter, la ceremonia contó con un jurado internacional compuesto por la actriz Bailee Madison, el Dr. Andrew Park, dermatólogo certificado y creador, y Gene Colón, vicepresidente sénior global de Asuntos Médicos y Comunicaciones de CeraVe.La ceremonia coronó a los primeros ganadores de
More news about: CeraVe
Jun 05, 2026, 11:35 ET CERAVE FEIERT ÜBER 100 PREISGEKRÖNTE CONTENT-SCHÖPFER AUS 22 LÄNDERN BEI DEN ERSTEN GLOBALEN CERAWARDS
Zeremonie wurde von einer internationalen Jury begleitet, zu der die Schauspielerin Bailee Madison, der Dermatologe und Erfinder Dr. Andrew Park und Gene Colón - Global SVP, Medical Affairs & Communications bei CeraVe - gehörten.Die Zeremonie krönte die ersten Gewinner der Global CerAwards
More news about: CeraVe
Jun 05, 2026, 11:26 ET CERAVE RÉCOMPENSE PLUS DE 100 CRÉATEURS DE CONTENU PRIMÉS DANS 22 PAYS POUR LA PREMIÈRE ÉDITION MONDIALE DES CERAWARDS
Stalter, la cérémonie a réuni un jury international composé de l'actrice Bailee Madison, du Dr Andrew Park, dermatologue certifié et créateur, et de Gene Colón, SVP mondial des affaires médicales et de la communication chez CeraVe.La cérémonie a couronné les premiers lauréats des Global CerAwards,
More news about: CeraVe
Jun 05, 2026, 11:20 ET CERAVE CELEBRA A MÁS DE 100 CREADORES DE CONTENIDO GALARDONADOS DE 22 PAÍSES PARA LOS PRIMEROS CERAWARDS GLOBALES
contó con un panel de jueces global que incluyó a la actriz Bailee Madison, el dermatólogo y creador certificado por la junta, el Dr. Andrew Park, y Gene Colón, vicepresidente senior global de Asuntos Médicos y Comunicaciones en CeraVe.La ceremonia coronó a los ganadores inaugurales de los Global
More news about: CeraVe
Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner
More news about: Vcare PharmaTech
Jun 05, 2026, 08:45 ET Morphy's To Host Live Auction Of Outstanding Western Art And Antiques On June 20, During The 36th Annual Old West Show In Santa Fe
circa 1937. The silversmith responsible for the fine decorations was Robert Schaezlein, who operated a shop out of San Francisco, and the tooling was by Gene Sisco. The saddle is in pristine condition, having been mounted on a horse only twice since its inception in 1937. It is accompanied by an original
More news about: Morphy Auctions
Jun 05, 2026, 08:02 ET CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
Stalter, the ceremony featured a global judging panel including actress Bailee Madison, Board-Certified Dermatologist and creator Dr. Andrew Park, and Gene Colón - Global SVP, Medical Affairs & Communications at CeraVe.The ceremony crowned the inaugural Global CerAwards winners, inducting them
More news about: CeraVe
Jun 05, 2026, 08:02 ET CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
Stalter, the ceremony featured a global judging panel including actress Bailee Madison, Board-Certified Dermatologist and creator Dr. Andrew Park, and Gene Colón - Global SVP, Medical Affairs & Communications at CeraVe.The ceremony crowned the inaugural Global CerAwards winners, inducting them
More news about: CeraVe
Jun 05, 2026, 08:00 ET Kihealth Announces Launch of Beta Intercept™, Advancing Real-Time Detection of Diabetes
assay utilizes an advanced droplet digital PCR (ddPCR) platform that simultaneously evaluates three distinct methylation sites within the insulin (INS) gene, significantly improving assay specificity, signal consistency, and analytical robustness compared with prior versions. The new product also incorporates
More news about: Kihealth
Jun 04, 2026, 17:06 ET Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
Bocunebart is designed to bind to and inhibit PACAP, a neuropeptide implicated in migraine pathophysiology through pathways distinct from calcitonin gene-related peptide (CGRP). This differentiated mechanism positions bocunebart as a potential alternative treatment option for patients who do not achieve
More news about: H. Lundbeck A/S
Jun 04, 2026, 17:04 ET Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
Bocunebart is designed to bind to and inhibit PACAP, a neuropeptide implicated in migraine pathophysiology through pathways distinct from calcitonin gene-related peptide (CGRP). This differentiated mechanism positions bocunebart as a potential alternative treatment option for patients who do not achieve
More news about: H. Lundbeck A/S
Jun 04, 2026, 16:20 ET Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit
More news about: Pacira BioSciences, Inc.
Jun 04, 2026, 12:01 ET ChoiceOne Bank Awards Scholarships to 19 High School Seniors
Fulton – Fenton Senior High SchoolAneko Nichol – Fraser High SchoolSimon Tunney – Fremont High SchoolMegan Mangalathet – Gene L. Klida Utica Academy for International StudiesLilly Goss – Kearsley High SchoolGavin Wandrie – Lapeer High SchoolMadelyn
More news about: ChoiceOne Bank
Jun 04, 2026, 10:30 ET Made Scientific and Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership to Advance Next-Generation iPSC-derived Cell Therapies
including induced natural killer (iNK) cells and induced mesenchymal stem cells (iMSCs), into Made Scientific's end-to-end CDMO offering for global cell and gene therapy innovators.
More news about: Made Scientific, Inc.
Jun 04, 2026, 09:00 ET Adventure Awaits: Go Off the Grid with NAVC at VMX 2027
"We live in a busy, noisy world where finding time to disconnect is almost impossible," said Gene O'Neill,
More news about: North American Veterinary Community (NAVC)
Jun 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and
More news about: Insmed Incorporated
Jun 04, 2026, 07:00 ET HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026
inhibitors demonstrated dose-dependent inhibition of cytokines and mRNA response, as well as dose-dependent down-regulation of interferon and IRF5-driven gene signatures, confirming pathway-level modulation in this model.In a cynomolgus monkey model, HotSpot's IRF5 inhibitors demonstrated complete
More news about: HotSpot Therapeutics
Jun 03, 2026, 23:36 ET MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
integrated capabilities spanning across discovery research and clinical development of allogeneic cell therapy assets, cord blood banking, and cell and gene therapy contract development and manufacturing (CDMO) business portfolios. MEDIPOST successfully commercialized the world's first regulatory-approved
More news about: MEDIPOST
Jun 03, 2026, 16:05 ET Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
ELVN-001ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. ELVN-001, a highly selective active-site TKI, has a mechanism of action that
More news about: Enliven Therapeutics, Inc.
Jun 03, 2026, 11:30 ET SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
aligned with regulatory expectations. It is truly exciting to play a critical role behind the advancement of innovative therapies - from biologics to gene therapies - bringing them closer to patients."Biologics represent a high-growth segment of the pharmaceutical market, alongside continued demand
More news about: SGS
Jun 03, 2026, 09:23 ET ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China
cell and gene therapy (CGT) CDMO services with GCP ClinPlus's robust capabilities in clinical trial execution and site management across China. The combined offering supports cutting-edge therapeutic modalities, including:In vivo CAR-TGene therapyCancer
More news about: ProBio Inc.
Jun 03, 2026, 09:16 ET Terapia de edição de bases de alta precisão demonstra eficácia duradoura sem VOCs e perfil de segurança favorável na doença falciforme
hemoglobina causado por mutações no gene da β-globina. Os pacientes podem apresentar anemia crônica, crises de dor recorrentes, infecções e danos progressivos aos órgãos, com casos graves se tornando fatais. Aproximadamente 3,5% da população global é portadora do gene da mutação falciforme e cerca de 300.000
More news about: CorrectSequence Therapeutics
Jun 03, 2026, 09:16 ET Hochpräzise Basen-Editierungstherapie zeigt dauerhafte VOC-freie Wirksamkeit und günstige Sicherheit bei Sichelzellanämie
Hämoglobinopathien eingestuft, die weltweit zu den häufigsten monogenen Erbkrankheiten gehören. Etwa 7 % der Weltbevölkerung tragen abnorme Hämoglobin-Gene in sich, und jährlich werden weltweit schätzungsweise 400.000 betroffene Kinder geboren.Basierend auf der gleichen tBE-Technologieplattform und
More news about: CorrectSequence Therapeutics